AFFX 9.77 Affymetrix $AFFX Hit a 52 week high of 9.89

New Post Public Reply Private Reply Replies (0) Message Board

Nov 13, 2014 at 10:10 AM

AFFX 9.77 Affymetrix $AFFX Hit a 52 week high of 9.89 Closing the day 09:45 at 9.77 -0.01 -0.10% With a day low of 9.77 and a total volume of 33,113.

AFFX Recent Posts: http://investorshangout.com/Affymetrix-AFFX-53256/

AFFX Affymetrix Recent Headline News

Intercept Pharmaceuticals Slumps: ICPT Falls 5.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - 1 hr 36 mins ago
Intercept Pharmaceuticals has been witnessing a negative trend in its current year earnings estimate and its share price has been falling for past few days
ANIP: 52.40 (-0.30), ICPT: 160.25 (-2.71), AMAG: 34.68 (-0.25), AFFX: 9.78 (unch)

Affymetrix Announces Webcast of Investor Day 2014 on Monday November 17, 2014
Business Wire - Wed Nov 12, 6:15AM CST
Affymetrix, Inc. (NASDAQ: AFFX) today announced that the company will host a live webcast in conjunction with its Investor Day on Monday, November 17, 2014 at 11:30 a.m. ET. Presentations from management will include a strategic update from Frank Witney, President & CEO, as well as a financial update from Gavin Wood, EVP & CFO.
AFFX: 9.78 (unch)

Affymetrix Launches Solution to Enable Cancer Researchers to Rapidly Map the Functional Impact of DNA Alterations on Gene Expression Profiles to Identify Potential Cancer Driver Events
Business Wire - Wed Nov 12, 5:30AM CST
Affymetrix (NASDAQ:AFFX) announced today the launch of Concurrent Molecular Analysis Profiling (CoMAP(TM)) capability, which enables cancer researchers to gain rapid insight into the functional impact of DNA copy number alterations by combining whole-genome copy number data with gene expression profiles to easily and cost-effectively visualize and identify cancer driver events.
AFFX: 9.78 (unch)

Orexigen (OREX) Worth Watching: Stock Soars 33.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 8:25AM CST
Orexigen (OREX) was a big mover last session, with shares surging over 33% on the day.
BIIB: 320.65 (-0.37), OREX: 5.98 (+0.14), AMAG: 34.68 (-0.25), AFFX: 9.78 (unch)

Achillion Pharmaceuticals (ACHN) Looks Strong: Stock Up 27.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 7:44AM CST
Achillion Pharmaceuticals (ACHN) was a big mover last session, as the company saw its shares surge a little over 27% on the day
HSKA: 16.00 (unch), ACHN: 14.36 (-0.49), ILMN: 190.96 (+4.04), AFFX: 9.78 (unch)

Global Cell and Tissue Culture Supplies Industry
PR Newswire - Mon Nov 10, 5:54PM CST
This report analyzes the worldwide markets for Cell and Tissue Culture Supplies in US$ Thousands by the following Product Segments: Media, Sera, and Reagents. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Latin America. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 67 companies including many key and niche players such as -
AFFX: 9.78 (unch)

BIND Therapeutics (BIND) Worth a Look: Stock Rises 5.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 7:30AM CST
BIND Therapeutics, Inc. (BIND) was a big mover last session, as the company saw its shares rise over 5% on the day.
AGEN: 2.99 (-0.02), AMAG: 34.68 (-0.25), BIND: 10.11 (+0.13), AFFX: 9.78 (unch)

Update: Affymetrix Posts Encouraging Q3 2014 Earnings
Andy Batts - at Seeking Alpha - Fri Nov 07, 7:41AM CST

AFFX: 9.78 (unch)

Looking for a Growth Stock? Why It is Time to Focus on Affymetrix (AFFX) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 7:40AM CST
Affymetrix is one such company that might be well-positioned for future earnings growth as this firm, which is in the healthcare sector, saw EPS growth of 150% last year, and is looking great for this year too
AFFX: 9.78 (unch)

Vertex Pharmaceuticals Seeks Approval for CF Combination - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Nov 06, 5:25PM CST
Priority review and timely approval would allow Vertex Pharmaceuticals (VRTX) to launch this combination in mid-15 in the U.S.
CYTK: 4.44 (+0.08), BIIB: 320.65 (-0.37), VRTX: 116.17 (-0.51), AFFX: 9.78 (unch)

Myriad Genetics Down on Earnings, Revenue Miss in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 2:30PM CST
Myriad Genetics (MYGN) believes the current trajectory of its Hereditary Cancer franchise puts it in a better position to achieve increased profitability and reach its targeted goals.
AGEN: 2.99 (-0.02), MYGN: 33.23 (+0.24), AMAG: 34.68 (-0.25), AFFX: 9.78 (unch)

Genomic Health Q3 Loss Narrower than Expected, Revenues Lag - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 1:50PM CST
In the third quarter of 2014, Genomic Health (GHDX) expanded Medicaid coverage for the Oncotype DX breast cancer test, extending coverage to more than 40 million Medicaid patients in 35 states .
AGEN: 2.99 (-0.02), AMAG: 34.68 (-0.25), GHDX: 33.18 (+0.19), AFFX: 9.78 (unch)

Celldex (CLDX) in Focus: Stock Tanks 21% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 7:50AM CST
Celldex has been witnessing a flat trend in its current year loss estimates and its share price has been falling for past few days
AGEN: 2.99 (-0.02), CLDX: 15.08 (+0.27), AMAG: 34.68 (-0.25), AFFX: 9.78 (unch)

Zacks' Bull Of The Day: Affymetrix
Zacks Investment Research - Seeking Alpha - Wed Nov 05, 1:43PM CST
Headquartered in Santa Clara, California, Affymetrix (NASDAQ: AFFX ) is a leading provider of microarray-based products and services to the global research community. The company utilizes its DNA chip technology in areas of gene expression,...
AFFX: 9.78 (unch)

Cytokinetics, Incorporated (CYTK) in Focus: Stock Surges 16.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 8:18AM CST
Cytokinetics, Incorporated (CYTK) was a big mover last session, as the company saw its shares rise by over 16% on the day.
AGEN: 2.99 (-0.02), CYTK: 4.44 (+0.08), AMAG: 34.68 (-0.25), AFFX: 9.78 (unch)

Earnings Estimates Moving Higher for Affymetrix (AFFX): Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 7:44AM CST
Affymetrix could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision front and its stock has seen decent short-term momentum
AFFX: 9.78 (unch)

Bull of the Day: Affymetrix (AFFX) - Bull of the Day
Neena Mishra - ZACKS - Wed Nov 05, 2:56AM CST
Bull of the Day: Affymetrix (AFFX) - Bull of the Day
AFFX: 9.78 (unch)

Integra Beats Earnings, Sales Up Y/Y, Outlook Lowered - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 10:20AM CST
Integra's (IART) total revenue during the reported quarter increased 7.7% year over year to $229.7 million, but missed the Zacks Consensus Estimate by 1.4%
AGEN: 2.99 (-0.02), IART: 48.35 (+0.12), AMAG: 34.68 (-0.25), AFFX: 9.78 (unch)

Zacks Rank #1 Additions for Monday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday
AGEN: 2.99 (-0.02), ACHC: 61.61 (+0.18), ALLE: 52.59 (+0.09), ADUS: 21.20 (-0.06), AFFX: 9.78 (unch)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Qapture Expands Global DeFi Reach with Key Acquisitions

Qapture Investments just made a move in the digital finance space that's promising to turn some heads. From acquiring Flammarion Partners to snapping up Hermetik Trading's DeFi strategies, this Bermuda-based investment manager isn't here to play. Led by Frederick Pye, the firm's gearing up for an industry takeover by blending regulation with innovative digital finance...

TVEyes Archive+: Revolutionizing Media Intelligence

TVEyes Archive+ Takes Media Intelligence to New Heights Dishing out another update here, folks. TVEyes, the media intelligence powerhouse, just kicked off something that's got the potential to change the strategic media game—they call it Archive+. This tool isn’t just plundering old tapes; we're talking nearly two damn decades worth of historical broadcasts and...

Plan A Bets on AI in High-Stakes M&A Arena

Digging Deeper with AI in M&A Deals Picture this: you’re at the table with a fat corporate M&A deal, eyes darting as you decipher numbers and nods, when out swings Plan A Technologies with their new ace up their sleeve—a stealth AI assessment tool armed to sharpen their technical due diligence. Unmasking the Tech Jigsaw Las Vegas-based Plan A Technologies hasn't just...

Vanda Pharmaceuticals Steps Into September Investor Talks

Vanda Pharmaceuticals Heads Into Key Investor Spotlights In the relentless quest for market edge, Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) is setting the stage for what could be some telling moments in September 2026. Investors with a keen interest in the pharmaceutical realm should seat themselves upfront as Vanda takes the floor in a series of pivotal conferences. Each...

Jamba's Cloud Whip: A Bold Blend in Beverage Scene

An Unexpected Shake-Up in the Beverage Game Folks, brace yourselves because Jamba's making some bold moves. I remember a time when a smoothie was just a smoothie, but now, they're stacking up a new deck with this fancy thing they're calling 'Cloud Whip'. It's basically a way to slap some extra protein onto your drink, with 10 grams coming at you like a freight train...

Equinix and CPP Investments Finalize $4B Data Center Deal

Equinix's Nordic Expansion: A Bold Move Ever seen a chess master make a move that completely shifts the board? That's what Equinix, Inc. and CPP Investments just pulled off with their acquisition of atNorth. With a hefty price tag of $4 billion, they're not just playing around. This deal puts Equinix at the center of the Nordic data hub, solidifying its foothold in a...

Codoxo Snags 2026 Award for AI Payment Innovation

Revolutionizing Healthcare Payment with AI Ah, healthcare and payments—two things that can make even the most patient folks lose their cool. But here comes Codoxo, shaking up this landscape with its Point Zero Payment Integrity solution, and someone's finally giving them the nod they deserve. For those of us who have been in the game for a while, this announcement is...

ECARX Leverages AI for Next-Gen Auto Intelligence

ECARX's Latest Ventures in AI-Driven Mobility ECARX is making waves with its recent announcement to integrate Tencent Cloud's WorkBuddy AI with the Flyme AIOS operating system. It's not a small tweak; it's a big leap forward in pushing AI boundaries in automobiles. If you're looking at ECARX Holdings Inc. (Nasdaq: ECX) as an investment, here's the meat and potatoes of...

STANLEY Dives Into Flooring: Strategic Move or Risky Bet?

STANLEY® Floors: The New Frontier? Who would've thought STANLEY®, the tool giant founded back in 1843, would dive headfirst into the flooring market? This isn’t just any leap; it's a strategic handshake with Area Floors, and they’re dragging along i4F’s renowned drop-lock tech for good measure. What does this mean for the flooring landscape and STANLEY's brand...

California's Insurance Shake-up: What It Means

There are plenty of rules in life that seem useless until suddenly they're not. California just passed a few fresh ones aiming to rein in the insurance sector. Zap your attention over to three new bills targeting fair insurance payouts and boosting coverage availability. It's a gust of wind in a typically frustrating insurance landscape, especially for the folks who've...